» Articles » PMID: 22810507

Altered MiRNA and Gene Expression in Acute Myeloid Leukemia with Complex Karyotype Identify Networks of Prognostic Relevance

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2012 Jul 20
PMID 22810507
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, the p53-miR-34a network has been identified to have an important role in tumorigenesis. As in acute myeloid leukemia with complex karyotype (CK-AML) TP53 alterations are the most common known molecular lesion, we further analyzed the p53-miR-34a axis in a large cohort of CK-AML with known TP53 status (TP53(altered), n=57; TP53(unaltered), n=31; altered indicates loss and/or mutation of TP53). Profiling microRNA (miRNA) expression delineated TP53 alteration-associated miRNA profiles, and identified miR-34a and miR-100 as the most significantly down- and upregulated miRNA, respectively. Moreover, we found a distinct miR-34a expression-linked gene expression profile enriched for genes belonging to p53-associated pathways, and implicated in cell cycle progression or apoptosis. Clinically, low miR-34a expression and TP53 alterations predicted for chemotherapy resistance and inferior outcome. Notably, in TP53(unaltered) CK-AML, high miR-34a expression predicted for inferior overall survival (OS), whereas in TP53(biallelic altered) CK-AML, high miR-34a expression pointed to better OS. Thus, detailed molecular profiling links impaired p53 to decreased miR-34a expression, but also identifies p53-independent miR-34a induction mechanisms as shown in TP53(biallelic altered) cell lines treated with 15-deoxy-Δ(12,14)-prostaglandin. An improved understanding of this mechanism might provide novel therapeutic options to restore miR-34a function and thereby induce cell cycle arrest and apoptosis in TP53(altered) CK-AML.

Citing Articles

Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia.

Abdellateif M, Hassan N, Kamel M, El-Meligui Y Oncol Res. 2024; 32(3):577-584.

PMID: 38361758 PMC: 10865737. DOI: 10.32604/or.2023.043026.


A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia.

Salehi A Med Oncol. 2024; 41(2):62.

PMID: 38253748 DOI: 10.1007/s12032-023-02286-1.


Small Non-Coding RNAs in Leukemia.

Balatti V, Croce C Cancers (Basel). 2022; 14(3).

PMID: 35158777 PMC: 8833386. DOI: 10.3390/cancers14030509.


Circular RNA ATAD1 is upregulated in acute myeloid leukemia and promotes cancer cell proliferation by downregulating miR-34b via promoter methylation.

Wu Y, Gao B, Qi X, Bai L, Li B, Bao H Oncol Lett. 2021; 22(5):799.

PMID: 34630706 PMC: 8477150. DOI: 10.3892/ol.2021.13060.


Deregulated expression of circular RNAs in acute myeloid leukemia.

Lux S, Blatte T, Gillissen B, Richter A, Cocciardi S, Skambraks S Blood Adv. 2021; 5(5):1490-1503.

PMID: 33683343 PMC: 7948263. DOI: 10.1182/bloodadvances.2020003230.